Researchers have identified 21 existing drugs that can treat Kovid-19

Researchers have identified 21 existing drugs that can treat Kovid-19

Let’s Start this Interesting Article Shared on

New York: A global team of scientists have identified 21 existing drugs that inhibit replication of SARS-CoV-2, the virus causing Kovid-19.
Specifically, four of these compounds were found to work synergistically with remedisvir as an existing standard-of-care regimen for Kovid-19, the study published in the journal Nature.
Sanides Bernheim Premedic Medicine Professor Sumit Chanda said, “Remedisavir has proved successful in reducing recovery time for hospitalized patients, but the drug is not effective for everyone. Discovery Institute in California, US.
“As the rate of infection continues to increase in the US and worldwide, there remains urgency to find inexpensive, effective, and readily available drugs that can complement the use of Remedisvir, as well as drugs that are prophylactic Or may be given at the first sign. Infection on an outpatient basis. ”
in study, The research The team performed extensive testing and validation studies, which included evaluating drugs on human lung biopsies that were infected with the virus.
They also evaluated drugs for synergy with remedisavir, and established dose-response relationships between drugs and antiviral activity.
Of the 21 drugs that block viral replication, scientists found that 13 have previously entered clinical trials for other indications and are effective at concentrations, or doses, that are likely safely achieved in Kovid-19 patients can be done.
Two are already approved by the US Food and Drug Administration: Estemizole (allergy), clofazamine (leprosy) and Remedisvir have received emergency use authorization from the agency (Kovid-19).
The four worked synergistically with Remedisvir, a chloroquine derivative hefangchin A (tetrandine), an antimalarial drug that reached Phase 3 clinical trials.
Chanda said, “This study significantly expands potential therapeutic options for Kovid-19 patients, especially because there are already many molecules of clinical safety data in humans.”
“This report provides the scientific community with a large arsenal of potential weapons that can help bring the ongoing global epidemic to heel.”
Researchers are currently testing all 21 compounds in small animal models and “mini lung,” or lung organoids, that mimic human tissue.
If these studies are favorable, the team will contact the US FDA to discuss clinical trials evaluating drugs as a treatment for Covid-19.
“Based on our current analysis, clofazimine, hafangchin A, epilimod, and ONO 5334 represent the best near-term options for an effective Kovid-19 treatment,” Chanda said.
“While some of these drugs are currently in clinical trials for Kovid-19, we believe it is important to pursue additional drug candidates, so we have several therapeutic options if SARS-COV-2 drug Resistant. ”
The drugs were first identified by high throughput screening of more than 12,000 drugs derived from the RFRAME Drug Reposing Collection – the most comprehensive drug reposing collection of compounds that have been approved by the FDA for other diseases or that have been identified as human Tested for safety. .
In the video: Kovid-19: Researchers have identified 21 existing drugs that can treat coronavirus


Leave a Reply

Your email address will not be published. Required fields are marked *